Clinical trials: Non-Segmental Vitiligo, open to volunteers
Non-segmental Vitiligo
An Open-label Single Center, Proof of Concept Study Evaluating the Efficacy of Roflumilast Foam 0.3% in Pediatric Patients With Non-Segmental Vitiligo (NSV)
An open-label single center, proof of concept study evaluating the efficacy of Roflumilast foam 0.3% in pediatric subjects with Non-Segmental Vitiligo (NSV)
- Trial name
- NCT07105254
- Testing
- Roflumilast topical 0.3% foam
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Derm Texas, PLLC
Non-segmental Vitiligo
A Phase IIb Dose-ranging Study to Assess the Efficacy and Safety of GIA632 in Participants With Non-segmental Vitiligo
The main purpose of this multicenter, randomized, double-blind, placebo-controlled Phase 2b study is to investigate the safety and efficacy of GIA632 in participants with NSV and to identify the optimal dose to be promoted into…
- Trial name
- VITESS (NCT07431177)
- Testing
- GIA632
- Where
- 83 sites in United States, Argentina and 10 more
- Volunteers
- 210 people
- Sponsor
- Novartis Pharmaceuticals
Non-Segmental Vitiligo (NSV)
Ruxolitinib Cream Combined With Corticosteroids for Progressive Non-Segmental Vitiligo: A Multicenter Real-World Study
This study is a prospective, multicenter, real-world observational study to assess the clinical efficacy and safety of topical 1.5% Ruxolitinib phosphate cream used in combination with systemic corticosteroids in a real-world…
- Trial name
- NCT07673640
- Testing
- 1.5% Ruxolitinib Phosphate Cream (Opzelura), Corticosteroid Therapy
- Where
- 20 sites in China
- Volunteers
- 300 people
- Sponsor
- ShanShan Li
Vitiligo
Topical Methotrexate with Fractional CO2 Laser in Treatment of Non Segmental Vitiligo
This prospective, within subject clinical trial aims to evaluate the efficacy of combining fractional CO2 laser with topical methotrexate versus topical methotrexate alone in treating non-segmental vitiligo.
- Trial name
- NCT06877455
- Testing
- Fractional CO2 laser assisted PDT
- Volunteers
- 50 people
- Sponsor
- Assiut University
Adult Subjects With Non-Segmental Vitiligo
A Multicenter, Randomized, Parallel-Group, Double-Blind, Placebo-Controlled Phase II Clinical Trial to Evaluate the Efficacy and Safety of QY201 Tablets in Subjects With Non-Segmental Vitiligo
To evaluate the efficacy of QY201 Tablets in adult subjects with non-segmental vitiligo, and to provide evidence for dose selection in the confirmatory Phase III clinical trial.
- Trial name
- NCT07712523
- Testing
- QY201 Tablets(5mg）, QY201 Tablets（10mg）, QY201 Tablets（20mg）
- Where
- China
- Volunteers
- 200 people
- Sponsor
- E-nitiate Biopharmaceuticals (Hangzhou) Co., Ltd.
Non-Segmental Vitiligo (NSV)
A Study of EB06 Versus Placebo in Adults With Moderate to Severe Non-segmental Vitiligo
The purpose of this study is to evaluate the safety and efficacy of EB06 intravenous infusion (loading dose of 20mg/kg followed by a maintenance dose of 10mg/kg) compared with placebo in adults with moderate to severe…
- Trial name
- NCT07889492
- Testing
- EB06
- Where
- 5 sites in Canada, Panama
- Volunteers
- 80 people
- Sponsor
- Edesa Biotech Inc.
Vitiligo
The Value of Adding Mini-oral Pulse Steroid Therapy in Preventing Peri-lesional Halo Post Non-cultured Epidermal Cell Suspension (NCES) in Cases With Stable Segmental and Non-acral Vitiligo.
The goal of this clinical trial is to learn if adding mini-oral pulse steroid therapy improves the results of non-cultured epidermal cell suspension (NCES) surgery in patients with stable vitiligo.
- Trial name
- NCT07472816
- Testing
- Non-cultured epidermal cell suspension (NCES) surgery, Oral mini pulse, Excimer Sessions
- Where
- Egypt
- Volunteers
- 60 people
- Sponsor
- Cairo University
Non-Segmental Vitiligo
A Study to Learn How Effective, Safe, and Tolerable Upadacitinib is for Young Participants With Non-segmental Vitiligo
Vitiligo is a common, long-lasting disease that happens when the immune system attacks melanocytes (skin cells that produce the skin-coloring pigment melanin) in the skin leading to loss of color.
- Trial name
- Ph3 Peds Viti (NCT07896434)
- Testing
- Upadacitinib
- Volunteers
- 154 people
- Sponsor
- AbbVie
Vitiligo
Two Trials to Evaluate TEV-53408 in Participants With Non-Segmental Vitiligo
The goal of these clinical trials is to learn if TEV-53408 can help adults with Non-Segmental Vitiligo (NSV). Vitiligo causes patches of skin to lose their color.
- Trial name
- NCT07920211
- Testing
- TEV-53408 Dose A, TEV-53408 Dose B
- Volunteers
- 1,020 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D LLC
Non-segmental Vitiligo
Efficacy and Safety Phase II Study of VC005 Tablets in Subjects With Non-segmental Vitiligo
This clinical trial is a multicenter, randomized, double-blind, controlled phase II clinical study
- Trial name
- NCT07172347
- Testing
- VC005 tablets
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Jiangsu vcare pharmaceutical technology co., LTD
Non-Segmental Vitiligo
A Study of VC005 Tablets in Adolescent Subjects With Non-Segmental Vitiligo
This study is a multicenter, open-label, non-randomized study designed to evaluate the pharmacokinetics (PK), safety, and preliminary efficacy of VC005 tablets in adolescent subjects with Non-Segmental Vitiligo
- Trial name
- NCT07828639
- Testing
- VC005 tablets
- Where
- China
- Volunteers
- 10 people
- Sponsor
- Jiangsu vcare pharmaceutical technology co., LTD
Non-Segmental Vitiligo (NSV)
Evaluation of the Efficacy and Safety of LW402 Tablets in Patients With Non-Segmental Vitiligo
This is a multicenter, randomized, double-blind, placebo-controlled Phase II clinical trial designed to assess the efficacy, safety, and tolerability of LW402 tablets in participants with non-segmental vitiligo.
- Trial name
- NCT07556471
- Testing
- Experimental LW402 Tablet
- Volunteers
- 180 people
- Sponsor
- Shanghai Longwood Biopharmaceuticals Co., Ltd.
Non Segmental Vitiligo
ICP-332 in Subjects With Non-segmental Vitiligo
This a phase II/III randomized, double-blind, placebo-controlled, parallel group, adaptive design, multi-center study to evaluate the efficacy and safety of ICP-332 in subjects with non-segmental vitiligo。The study consisted an…
- Trial name
- NCT07047612
- Testing
- ICP-332 Tablets
- Where
- 45 sites in China
- Volunteers
- 603 people
- Sponsor
- Beijing InnoCare Pharma Tech Co., Ltd.
Non-Segmental Vitiligo (NSV), Alopecia Areata
A Real World Study to Globally Assess Disease Burden in Adolescent and Adult Participants With Alopecia Areata, Vitiligo, or Hidradenitis Suppurativa
This study is to assess the burden of disease in adolescent and adult participants with moderate or severe alopecia areata (AA), non-segmental vitiligo (NSV), or moderate to severe hidradenitis suppurativa (HS) in a large global…
- Conditions
- Non-Segmental Vitiligo (NSV), Alopecia Areata, Hidradenitis Suppurativa
- Trial name
- MEASUREAAVitHS (NCT07136467)
- Where
- 116 sites in Argentina, Canada and 16 more
- Volunteers
- 2,795 people
- Sponsor
- AbbVie
Non-segmental Vitiligo
Phase 2 Study to Evaluate EI-001 in Non-segmental Vitiligo Patients
The primary purpose of this study is to evaluate whether the drug EI-001 can help improve vitiligo symptoms. EI-001 is a novel antibody drug that affects the immune system to decrease uncontrolled inflammation.
- Trial name
- NCT07223229
- Testing
- EI-001
- Where
- 8 sites in United States, Taiwan
- Volunteers
- 45 people
- Sponsor
- Elixiron Immunotherapeutics (Hong Kong) Ltd.
Non-segmental Vitiligo
Phase II/III Study of FXS5626 in Participants With Non-segmental Vitiligo
This is a multicenter, randomized, double-blind, placebo-controlled, adaptive seamless design, Phase II/III study evaluating the efficacy and safety of FXS5626 in participants with non-segmental vitiligo.
- Trial name
- NCT07840820
- Testing
- Intervention1: FXS5626 Tablets, Intervention2: FXS5626 Tablets, Intervention3: FXS5626 Tablets
- Where
- China
- Volunteers
- 480 people
- Sponsor
- Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.
Vitiligo, Non-Segmental Vitiligo (NSV)
Evaluation of Crisaborole 2% Versus Tacrolimus 0.1% Each Combined With Excimer Light in the Treatment of Stable Non-segmental Facial Vitiligo: a Prospective Randomized Controlled Study.
The goal of this clinical trial is to learn if topical application of crisaborole 2% ointment can treat stable patches of facial vitiligo in pediatrics and adult patients of both genders.
- Conditions
- Vitiligo, Non-Segmental Vitiligo (NSV), Stable Vitiligo
- Trial name
- NCT07904910
- Testing
- Crisaborole 2% topical ointment, tacrolimus 0.1%, Excimer Light therapy
- Where
- Egypt
- Volunteers
- 35 people
- Sponsor
- Cairo University
Vitiligo, Non-segmental Vitiligo
Comparison of Needling and Microneedling Plus Phototherapy in Localized Vitiligo Patients
This randomized controlled trial aims to compare the efficacy of needling versus microneedling, both followed by narrowband UVB therapy, in achieving repigmentation in patients with localized stable non-segmental vitiligo.
- Trial name
- NCT06991972
- Testing
- Needling + NBUVB, Microneedling + NBUVB
- Where
- Pakistan
- Volunteers
- 80 people
- Sponsor
- Khyber Teaching Hospital
Vitiligo
A Phase III Clinical Study to Evaluate the Efficacy and Safety of MH004 Ointment in Non-segmental Vitiligo
This is a randomized, double-blind, multicenter, placebo-controlled clinical study intended to evaluate the efficacy, safety and population pharmacokinetic profiles of MH004 ointment in eligible participants with NSV.
- Trial name
- NCT07682506
- Testing
- MH004 1.0% Ointment
- Where
- China
- Volunteers
- 405 people
- Sponsor
- Minghui Pharmaceutical (Hangzhou) Ltd
Vitiligo, Non-Segmental Vitiligo (NSV)
A Study of LY4005130 in Adult Participants With Non-Segmental Vitiligo
The purpose of this study is to evaluate how well LY4005130 is tolerated and what side effects may occur in participants with non-segmental vitiligo (NSV) when compared with placebo.
- Trial name
- NCT07533019
- Testing
- LY4005130
- Where
- 35 sites in United States, Belgium and 3 more
- Volunteers
- 66 people
- Sponsor
- Eli Lilly and Company